Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7098457 | 0.82 | NQO1 (0.37) | POLBCYP3A4 | |
| SCHEMBL8178745 | 0.82 | NQO1 (0.37) | POLBCYP3A4 | |
| SCHEMBL2757926 | 0.74 | POLB (0.52) | POLBEPHX1MEN1KMT2ALMNA | |
| SCHEMBL13678548 | 0.73 | CYP3A4 (0.39) | CYP3A4 | |
| SCHEMBL10906569 | 0.70 | POLB (0.48) | POLBEPHX1MEN1KMT2ALMNA | |
| SCHEMBL5541271 | 0.70 | POLB (0.48) | POLBEPHX1MEN1KMT2ALMNA | |
| SCHEMBL11453553 | 0.70 | NOTUM (0.37) | CYP3A4 | |
| SCHEMBL11273443 | 0.69 | MTOR (0.49) | CYP3A4EPHX1MEN1KMT2A | |
| SCHEMBL6831665 | 0.69 | — | — | |
| SCHEMBL3797211 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020099567-A1 | ENCAPSULATED BIOCIDES | LONZA LTD (CH) | 2020-05-22 | — | — | WO | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | POLB 326/4885CYP3A4 3584/4885EPHX1 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.